AEterna Zentaris (NASDAQ:AEZS) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a report released on Thursday, AnalystRatings.com reports.

“We maintain our Buy rating of AEZS and our 12-month price target of $5.50 per share. We derive our price target using a risk- adjusted net present value analysis of potential US and EU royalties, discounted at 18%, to reach a total rNPV of $66M for the royalty streams.”,” the firm’s analyst wrote.

Other analysts have also issued research reports about the company. TheStreet lowered AEterna Zentaris from a c- rating to a d rating in a report on Thursday, June 13th. ValuEngine lowered AEterna Zentaris from a buy rating to a hold rating in a report on Tuesday, June 11th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of Buy and an average price target of $3.17.

Shares of AEZS opened at $2.10 on Thursday. AEterna Zentaris has a one year low of $1.29 and a one year high of $5.57. The firm has a market capitalization of $35.35 million, a P/E ratio of 8.40 and a beta of 1.26. The business has a fifty day moving average of $2.57 and a 200 day moving average of $3.44.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported $0.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.15. AEterna Zentaris had a negative return on equity of 1,428.66% and a negative net margin of 536.79%. The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.20 million. On average, research analysts anticipate that AEterna Zentaris will post 1.77 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in AEZS. AJO LP bought a new stake in AEterna Zentaris during the first quarter valued at about $1,031,000. Acadian Asset Management LLC grew its holdings in AEterna Zentaris by 271.2% during the first quarter. Acadian Asset Management LLC now owns 167,222 shares of the biopharmaceutical company’s stock valued at $777,000 after purchasing an additional 122,173 shares during the period. BlackRock Inc. bought a new stake in AEterna Zentaris during the second quarter valued at about $135,000. Virtu Financial LLC bought a new stake in AEterna Zentaris during the first quarter valued at about $179,000. Finally, Jane Street Group LLC bought a new stake in AEterna Zentaris during the fourth quarter valued at about $30,000. 13.32% of the stock is owned by institutional investors and hedge funds.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Read More: Average Daily Trade Volume Explained

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.